Takeda Sees Turnaround Next Year as New Drugs Bolster Growth
This article is for subscribers only.
Takeda Pharmaceutical Co. expects to see a turnaround next fiscal year as new products bolster growth at Asia’s largest drugmaker, which is forecast to post its second consecutive annual profit decline in the 12 months ending March.
“This year is an investment year. Next year, we should start to see sales growth and also profit growth, core earnings growth,” Chief Operating Officer Christophe Weber said in an interview in Singapore today. “That’s for us a turnaround that should happen.”